-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $112

Benzinga·02/05/2026 20:57:27
Listen to the news
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $131 to $112.